English
简体中文
Total: £ 56.28
Published Date: 2026-03-25 | Pages: 123 | Tables: 125 | Pharma & Healthcare
The global Oncogene Inhibitors market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Oncogene Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for Oncogene Inhibitors is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Oncogene Inhibitors is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Oncogene Inhibitors include AstraZeneca, Merck Sharp & Dohme, Pfizer, Celgene, Novartis, Pacira BioSciences, Johnson & Johnson, Fresenius Kabi, Assertio, Takeda Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Oncogene Inhibitors market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oncogene Inhibitors. The Oncogene Inhibitors market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Oncogene Inhibitors market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Oncogene Inhibitors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZeneca
Merck Sharp & Dohme
Pfizer
Celgene
Novartis
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi
Assertio
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
Segment by Type
Oral
Injection
by Application
Cancer Treatment
Clinical Research
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Oncogene Inhibitors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Oncogene Inhibitors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Oncogene Inhibitors Market Overview
1.1 Product Definition
1.2 Oncogene Inhibitors by Type
1.2.1 Global Oncogene Inhibitors Market Value by Type: 2025 vs 2032
1.2.2 Oral
1.2.3 Injection
1.3 Oncogene Inhibitors by Application
1.3.1 Global Oncogene Inhibitors Market Value by Application: 2025 vs 2032
1.3.2 Cancer Treatment
1.3.3 Clinical Research
1.3.4 Other
1.4 Global Oncogene Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Oncogene Inhibitors Revenue 2021–2032
1.4.2 Global Oncogene Inhibitors Sales 2021–2032
1.4.3 Global Oncogene Inhibitors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Oncogene Inhibitors Market Competition by Manufacturers
2.1 Global Oncogene Inhibitors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Oncogene Inhibitors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Oncogene Inhibitors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Oncogene Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Oncogene Inhibitors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Oncogene Inhibitors, Product Types and Applications
2.7 Global Key Manufacturers of Oncogene Inhibitors, Date of Entry into the Industry
2.8 Global Oncogene Inhibitors Market Competitive Situation and Trends
2.8.1 Global Oncogene Inhibitors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Oncogene Inhibitors Players Market Share by Revenue
2.8.3 Global Oncogene Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oncogene Inhibitors Market Scenario by Region
3.1 Global Oncogene Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Oncogene Inhibitors Sales by Region: 2021–2032
3.2.1 Global Oncogene Inhibitors Sales by Region: 2021–2026
3.2.2 Global Oncogene Inhibitors Sales by Region: 2027–2032
3.3 Global Oncogene Inhibitors Revenue by Region: 2021–2032
3.3.1 Global Oncogene Inhibitors Revenue by Region: 2021–2026
3.3.2 Global Oncogene Inhibitors Revenue by Region: 2027–2032
3.4 North America Oncogene Inhibitors Market Facts & Figures by Country
3.4.1 North America Oncogene Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Oncogene Inhibitors Sales by Country (2021–2032)
3.4.3 North America Oncogene Inhibitors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncogene Inhibitors Market Facts & Figures by Country
3.5.1 Europe Oncogene Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Oncogene Inhibitors Sales by Country (2021–2032)
3.5.3 Europe Oncogene Inhibitors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncogene Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Oncogene Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Oncogene Inhibitors Sales by Region (2021–2032)
3.6.3 Asia Pacific Oncogene Inhibitors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oncogene Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Oncogene Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Oncogene Inhibitors Sales by Country (2021–2032)
3.7.3 Latin America Oncogene Inhibitors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oncogene Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncogene Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Oncogene Inhibitors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Oncogene Inhibitors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncogene Inhibitors Sales by Type (2021–2032)
4.1.1 Global Oncogene Inhibitors Sales by Type (2021–2026)
4.1.2 Global Oncogene Inhibitors Sales by Type (2027–2032)
4.1.3 Global Oncogene Inhibitors Sales Market Share by Type (2021–2032)
4.2 Global Oncogene Inhibitors Revenue by Type (2021–2032)
4.2.1 Global Oncogene Inhibitors Revenue by Type (2021–2026)
4.2.2 Global Oncogene Inhibitors Revenue by Type (2027–2032)
4.2.3 Global Oncogene Inhibitors Revenue Market Share by Type (2021–2032)
4.3 Global Oncogene Inhibitors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Oncogene Inhibitors Sales by Application (2021–2032)
5.1.1 Global Oncogene Inhibitors Sales by Application (2021–2026)
5.1.2 Global Oncogene Inhibitors Sales by Application (2027–2032)
5.1.3 Global Oncogene Inhibitors Sales Market Share by Application (2021–2032)
5.2 Global Oncogene Inhibitors Revenue by Application (2021–2032)
5.2.1 Global Oncogene Inhibitors Revenue by Application (2021–2026)
5.2.2 Global Oncogene Inhibitors Revenue by Application (2027–2032)
5.2.3 Global Oncogene Inhibitors Revenue Market Share by Application (2021–2032)
5.3 Global Oncogene Inhibitors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca Oncogene Inhibitors Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Merck Sharp & Dohme
6.2.1 Merck Sharp & Dohme Company Information
6.2.2 Merck Sharp & Dohme Description and Business Overview
6.2.3 Merck Sharp & Dohme Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Merck Sharp & Dohme Oncogene Inhibitors Product Portfolio
6.2.5 Merck Sharp & Dohme Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Pfizer Oncogene Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Celgene
6.4.1 Celgene Company Information
6.4.2 Celgene Description and Business Overview
6.4.3 Celgene Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Celgene Oncogene Inhibitors Product Portfolio
6.4.5 Celgene Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Novartis Oncogene Inhibitors Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Pacira BioSciences
6.6.1 Pacira BioSciences Company Information
6.6.2 Pacira BioSciences Description and Business Overview
6.6.3 Pacira BioSciences Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Pacira BioSciences Oncogene Inhibitors Product Portfolio
6.6.5 Pacira BioSciences Recent Developments/Updates
6.7 Johnson & Johnson
6.7.1 Johnson & Johnson Company Information
6.7.2 Johnson & Johnson Description and Business Overview
6.7.3 Johnson & Johnson Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Johnson & Johnson Oncogene Inhibitors Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Fresenius Kabi
6.8.1 Fresenius Kabi Company Information
6.8.2 Fresenius Kabi Description and Business Overview
6.8.3 Fresenius Kabi Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Fresenius Kabi Oncogene Inhibitors Product Portfolio
6.8.5 Fresenius Kabi Recent Developments/Updates
6.9 Assertio
6.9.1 Assertio Company Information
6.9.2 Assertio Description and Business Overview
6.9.3 Assertio Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Assertio Oncogene Inhibitors Product Portfolio
6.9.5 Assertio Recent Developments/Updates
6.10 Takeda Pharmaceutical
6.10.1 Takeda Pharmaceutical Company Information
6.10.2 Takeda Pharmaceutical Description and Business Overview
6.10.3 Takeda Pharmaceutical Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Takeda Pharmaceutical Oncogene Inhibitors Product Portfolio
6.10.5 Takeda Pharmaceutical Recent Developments/Updates
6.11 Teva Pharmaceutical Industries
6.11.1 Teva Pharmaceutical Industries Company Information
6.11.2 Teva Pharmaceutical Industries Description and Business Overview
6.11.3 Teva Pharmaceutical Industries Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Teva Pharmaceutical Industries Oncogene Inhibitors Product Portfolio
6.11.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.12 Cipla
6.12.1 Cipla Company Information
6.12.2 Cipla Description and Business Overview
6.12.3 Cipla Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Cipla Oncogene Inhibitors Product Portfolio
6.12.5 Cipla Recent Developments/Updates
6.13 Sun Pharmaceutical Industries
6.13.1 Sun Pharmaceutical Industries Company Information
6.13.2 Sun Pharmaceutical Industries Description and Business Overview
6.13.3 Sun Pharmaceutical Industries Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Sun Pharmaceutical Industries Oncogene Inhibitors Product Portfolio
6.13.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.14 Shanghai Fosun Pharmaceutical
6.14.1 Shanghai Fosun Pharmaceutical Company Information
6.14.2 Shanghai Fosun Pharmaceutical Description and Business Overview
6.14.3 Shanghai Fosun Pharmaceutical Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Shanghai Fosun Pharmaceutical Oncogene Inhibitors Product Portfolio
6.14.5 Shanghai Fosun Pharmaceutical Recent Developments/Updates
6.15 Ingenus
6.15.1 Ingenus Company Information
6.15.2 Ingenus Description and Business Overview
6.15.3 Ingenus Oncogene Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Ingenus Oncogene Inhibitors Product Portfolio
6.15.5 Ingenus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncogene Inhibitors Industry Chain Analysis
7.2 Oncogene Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncogene Inhibitors Production Mode & Process Analysis
7.4 Oncogene Inhibitors Sales and Marketing
7.4.1 Oncogene Inhibitors Sales Channels
7.4.2 Oncogene Inhibitors Distributors
7.5 Oncogene Inhibitors Customer Analysis
8 Oncogene Inhibitors Market Dynamics
8.1 Oncogene Inhibitors Industry Trends
8.2 Oncogene Inhibitors Market Drivers
8.3 Oncogene Inhibitors Market Challenges
8.4 Oncogene Inhibitors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Oncogene Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Oncogene Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Oncogene Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Oncogene Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Oncogene Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Oncogene Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Oncogene Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Oncogene Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Oncogene Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Oncogene Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Oncogene Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Oncogene Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oncogene Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Oncogene Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oncogene Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Oncogene Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global Oncogene Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Oncogene Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global Oncogene Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Oncogene Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Oncogene Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Oncogene Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Oncogene Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Oncogene Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Oncogene Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America Oncogene Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America Oncogene Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Oncogene Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Oncogene Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Oncogene Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe Oncogene Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe Oncogene Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Oncogene Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Oncogene Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Oncogene Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Oncogene Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Oncogene Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Oncogene Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Oncogene Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Oncogene Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America Oncogene Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America Oncogene Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Oncogene Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Oncogene Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Oncogene Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Oncogene Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Oncogene Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Oncogene Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Oncogene Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global Oncogene Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global Oncogene Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Oncogene Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Oncogene Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Oncogene Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Oncogene Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Oncogene Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Oncogene Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Oncogene Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Oncogene Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global Oncogene Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global Oncogene Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Oncogene Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Oncogene Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Oncogene Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Oncogene Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Oncogene Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Oncogene Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Oncogene Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AstraZeneca Oncogene Inhibitors Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Merck Sharp & Dohme Company Information
Table 76. Merck Sharp & Dohme Description and Business Overview
Table 77. Merck Sharp & Dohme Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Merck Sharp & Dohme Oncogene Inhibitors Product
Table 79. Merck Sharp & Dohme Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Pfizer Oncogene Inhibitors Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Celgene Company Information
Table 86. Celgene Description and Business Overview
Table 87. Celgene Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Celgene Oncogene Inhibitors Product
Table 89. Celgene Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Novartis Oncogene Inhibitors Product
Table 94. Novartis Recent Developments/Updates
Table 95. Pacira BioSciences Company Information
Table 96. Pacira BioSciences Description and Business Overview
Table 97. Pacira BioSciences Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Pacira BioSciences Oncogene Inhibitors Product
Table 99. Pacira BioSciences Recent Developments/Updates
Table 100. Johnson & Johnson Company Information
Table 101. Johnson & Johnson Description and Business Overview
Table 102. Johnson & Johnson Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Johnson & Johnson Oncogene Inhibitors Product
Table 104. Johnson & Johnson Recent Developments/Updates
Table 105. Fresenius Kabi Company Information
Table 106. Fresenius Kabi Description and Business Overview
Table 107. Fresenius Kabi Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Fresenius Kabi Oncogene Inhibitors Product
Table 109. Fresenius Kabi Recent Developments/Updates
Table 110. Assertio Company Information
Table 111. Assertio Description and Business Overview
Table 112. Assertio Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Assertio Oncogene Inhibitors Product
Table 114. Assertio Recent Developments/Updates
Table 115. Takeda Pharmaceutical Company Information
Table 116. Takeda Pharmaceutical Description and Business Overview
Table 117. Takeda Pharmaceutical Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Takeda Pharmaceutical Oncogene Inhibitors Product
Table 119. Takeda Pharmaceutical Recent Developments/Updates
Table 120. Teva Pharmaceutical Industries Company Information
Table 121. Teva Pharmaceutical Industries Description and Business Overview
Table 122. Teva Pharmaceutical Industries Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Teva Pharmaceutical Industries Oncogene Inhibitors Product
Table 124. Teva Pharmaceutical Industries Recent Developments/Updates
Table 125. Cipla Company Information
Table 126. Cipla Description and Business Overview
Table 127. Cipla Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Cipla Oncogene Inhibitors Product
Table 129. Cipla Recent Developments/Updates
Table 130. Sun Pharmaceutical Industries Company Information
Table 131. Sun Pharmaceutical Industries Description and Business Overview
Table 132. Sun Pharmaceutical Industries Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Sun Pharmaceutical Industries Oncogene Inhibitors Product
Table 134. Sun Pharmaceutical Industries Recent Developments/Updates
Table 135. Shanghai Fosun Pharmaceutical Company Information
Table 136. Shanghai Fosun Pharmaceutical Description and Business Overview
Table 137. Shanghai Fosun Pharmaceutical Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Shanghai Fosun Pharmaceutical Oncogene Inhibitors Product
Table 139. Shanghai Fosun Pharmaceutical Recent Developments/Updates
Table 140. Ingenus Company Information
Table 141. Ingenus Description and Business Overview
Table 142. Ingenus Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Ingenus Oncogene Inhibitors Product
Table 144. Ingenus Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Oncogene Inhibitors Distributors List
Table 148. Oncogene Inhibitors Customers List
Table 149. Oncogene Inhibitors Market Trends
Table 150. Oncogene Inhibitors Market Drivers
Table 151. Oncogene Inhibitors Market Challenges
Table 152. Oncogene Inhibitors Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oncogene Inhibitors
Figure 2. Global Oncogene Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Oncogene Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Oral Product Picture
Figure 5. Injection Product Picture
Figure 6. Global Oncogene Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Oncogene Inhibitors Market Share by Application: 2025 & 2032
Figure 8. Cancer Treatment
Figure 9. Clinical Research
Figure 10. Other
Figure 11. Global Oncogene Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Oncogene Inhibitors Market Size (US$ Million), 2021–2032
Figure 13. Global Oncogene Inhibitors Sales (K Units), 2021–2032
Figure 14. Global Oncogene Inhibitors Average Price (US$/Unit), 2021–2032
Figure 15. Oncogene Inhibitors Report Years Considered
Figure 16. Oncogene Inhibitors Sales Share by Manufacturers in 2025
Figure 17. Global Oncogene Inhibitors Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Oncogene Inhibitors Players: Market Share by Revenue in Oncogene Inhibitors in 2025
Figure 19. Oncogene Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Oncogene Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Oncogene Inhibitors Sales Market Share by Country (2021–2032)
Figure 22. North America Oncogene Inhibitors Revenue Market Share by Country (2021–2032)
Figure 23. United States Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Oncogene Inhibitors Sales Market Share by Country (2021–2032)
Figure 26. Europe Oncogene Inhibitors Revenue Market Share by Country (2021–2032)
Figure 27. Germany Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Oncogene Inhibitors Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Oncogene Inhibitors Revenue Market Share by Region (2021–2032)
Figure 34. China Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Oncogene Inhibitors Sales Market Share by Country (2021–2032)
Figure 42. Latin America Oncogene Inhibitors Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Oncogene Inhibitors Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Oncogene Inhibitors Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Oncogene Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Oncogene Inhibitors by Type (2021–2032)
Figure 53. Global Revenue Market Share of Oncogene Inhibitors by Type (2021–2032)
Figure 54. Global Oncogene Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Oncogene Inhibitors by Application (2021–2032)
Figure 56. Global Revenue Market Share of Oncogene Inhibitors by Application (2021–2032)
Figure 57. Global Oncogene Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 58. Oncogene Inhibitors Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
